Detail of "93107-08-5"

CAS Number:
93107-08-5
Name:
3-Quinolinecarboxylicacid, 1-cyclopropyl-6-fluoro-1,4-dihydro-4-oxo-7-(1-piperazinyl)-,hydrochloride (1:1)
Superlist Name:
Ciprofloxacin hydrochloride
Molecular Structure:
Formula:
C₁₇H₁₈FN₃O₃^.HCl
Molecular Weight:
367.80
Synonyms:
3-Quinolinecarboxylic acid, 1-cyclopropyl-6-fluoro-1,4-dihydro-4-oxo-;1-Cyclopropyl-6-fluoro-1,4-dihydro-4-oxo-7-(1-piperazinyl)-3-;Ciprofloxacin monohydrochloride;
Melting Point:
>300 °C
Boiling Point:
581.8 °C at 760 mmHg
Flash Point:
305.6 °C

Famous Chemical Enterprises

Livzon
Total
Shell
Dupont
Exxonmobil
Akzonobel
Basf
Bayer
BP

Other Products

Supplier Location
Supplier Location
- China (Mainland)(20)
- India(3)
Business Type
Business Type
- Manufacturers(0)
- Trading Company(14)
Certificates
Certificates
- ISO (0)
- Production License (0)

Please post your buying leads>>

Display：

Manufacturer
Enterprise Authentication
Suppiers of more reward points first
New supplier

Please post your buying leads,so that our qualified suppliers will soon contact you!
*Required Fields

Reference

US Food and Drug Administration approval of ciprofloxacin hydrochloride for management of postexposure inhalational anthrax: US Food and Drug Administration approval of ciprofloxacin hydrochloride for management of postexposure inhalational anthrax.In this study， 93107-08-5 and 1406-05-9 are also used. Meyerhoff, Andrea; Albrecht, Renata; Meyer, Joette M.; Dionne, Peter; Higgins, Karen; Murphy, Dianne (US Food and Drug Administration, Rockville, MD, USA). Clinical Infectious Diseases, 39(3), 303-308 (English) 2004 University of Chicago Press. CODEN: CIDIEL. ISSN: 1058-4838. DOCUMENT TYPE: Journal CA Section: 1 (Pharmacology) In August 2000, the US Food and Drug Administration (FDA) approved ciprofloxacin hydrochloride (Cipro; Bayer) for management of postexposure inhalational anthrax. This was the first antimicrobial drug approved by the FDA for use in treating an infection due to a biol. agent used intentionally. The terrorist attacks of 2001 involving anthrax underscore the imperative that safe and effective drugs to manage such infections be readily available in the United States. The approval of ciprofloxacin hydrochloride, which was made on the basis of a surrogate human marker of efficacy, made extensive use of data from an animal model of disease. This represents a new direction in the development of efficacy data in support of drug approval and facilitates the availability of those drugs for which there is an urgent need. This article presents the scientific data and regulatory mechanism that supported the approval of ciprofloxacin hydrochloride for management of postexposure of inhalational anthrax. .

Use of fluoroquinone antibiotics for the treatment of plague: Use of fluoroquinone antibiotics for the treatment of plague. Brooks, Timothy John Gilby; Lever, Mark Stephen; Steward, Jacqueline (The Secretary of State for Defence, UK). Brit. UK Pat. Appl. GB 2403653 A1 12 Jan 2005, 43 pp. (English). (United Kingdom). CODEN: BAXXDU. CLASS: ICM: A61K031-4709. ICS: A61P031-04. APPLICATION: GB 2003-16139 10 Jul 2003. DOCUMENT TYPE: Patent CA Section: 1 (Pharmacology) This invention relates to the use of a compd. 186826-86-8 and 93107-08-5 which are cas registry numbers of chemicals are mentioned. of the formula I: and pharmaceutically acceptable salts thereof, wherein R1 is selected from the group consisting of hydrogen, lower-alkyl, alkoxy, alkenyl, alkynyl, aryl, aryloxy, cycloalkyl, halogen, haloalkyl, amino, imino, nitro, cyano, formyl; wherein R2 is selected from the group comprising of heterocycle, substituted heterocycle, amino, imino; and wherein when R1 is hydrogen, R2 is not 1-piperazinyl and when R2 is 1-piperazinyl, R1 is not hydrogen, for the manuf. of a medicament for the treatment of plague. This invention also relates to the use of the aforementioned compds. for the manuf. of a medicament for prophylactic administration to prevent plague. .

Detail of "93107-08-5"

3-Quinolinecarboxylicacid, 1-cyclopropyl-6-fluoro-1,4-dihydro-4-oxo-7-(1-piperazinyl)-,hydrochloride (1:1)

Famous Chemical Enterprises

Related products

Other Products

Supplier Location

Business Type

Certificates

CAS No.93107-08-5 Ciprofloxacin hydrochloride

CAS No.93107-08-5 Ciprofloxacin hydrochloride

CAS No.93107-08-5 Ciprofloxacin hydrochloride

CAS No.93107-08-5 Ciprofloxacin hydrochloride

CAS No.93107-08-5 Ciprofloxacin hydrochloride

CAS No.93107-08-5 Ciprofloxacin hydrochloride

CAS No.93107-08-5 Ciprofloxacin hydrochloride

CAS No.93107-08-5 Ciprofloxacin hydrochloride

CAS No.93107-08-5 Ciprofloxacin hydrochloride

CAS No.93107-08-5 Ciprofloxacin hydrochloride

CAS No.93107-08-5 Ciprofloxacin hydrochloride

CAS No.93107-08-5 Ciprofloxacin hydrochloride

CAS No.93107-08-5 Ciprofloxacin hydrochloride

CAS No.93107-08-5 Ciprofloxacin hydrochloride

CAS No.93107-08-5 Ciprofloxacin hydrochloride

CAS No.93107-08-5 Ciprofloxacin hydrochloride

CAS No.93107-08-5 Ciprofloxacin hydrochloride

CAS No.93107-08-5 Ciprofloxacin hydrochloride

CAS No.93107-08-5 Ciprofloxacin hydrochloride

CAS No.93107-08-5 Ciprofloxacin hydrochloride

CAS No.93107-08-5 Ciprofloxacin hydrochloride

CAS No.93107-08-5 Ciprofloxacin hydrochloride

CAS No.93107-08-5 Ciprofloxacin hydrochloride

Reference